{"id":501817,"date":"2020-08-12T13:35:34","date_gmt":"2020-08-12T13:35:34","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=501817"},"modified":"2020-08-12T13:35:34","modified_gmt":"2020-08-12T13:35:34","slug":"acromegaly-epidemiology-forecast-till-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acromegaly-epidemiology-forecast-till-2030_501817.html","title":{"rendered":"Acromegaly Epidemiology Forecast till 2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Acromegaly Epidemiology Forecast till 2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Acromegaly Epidemiology Forecast till 2030\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP      <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Acromegaly Epidemiology Forecast to 2030&#8242; report delivers an in-depth understanding of the disease, historical and forecasted Acromegaly epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/div>\n<p style=\"text-align: justify;\">Acromegaly is a rare and chronic disorder characterized by excess growth hormone secretion and elevated insulin-like growth factor-1 levels, most often caused by a pituitary Adenoma.<\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/acromegaly-epidemiology-forecast\" target=\"_blank\">Acromegaly&nbsp;Epidemiology Insights<\/a><\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The total prevalent cases of Acromegaly in 2017 was 64,508<\/li>\n<li>The diagnosed patient pool cases in 2017 was 49,814&nbsp;<\/li>\n<li>The prevalent population of Acromegaly in the United States in 2017 was 28,671 &nbsp;<\/li>\n<li>\n<p>The prevalent cases of Acromegaly in Japan in 2017 was 10,690<\/p>\n<\/li>\n<li>\n<p>EU5 countries occupied around 38.98% of the patient pool amongst 7MM in 2017<\/p>\n<\/li>\n<li>The diagnosed cases of Acromegaly based on types of Adenomas in the US in 2017:\n<ul>\n<li>18,349 &#8211; Macroadenomas<\/li>\n<li>4,587 &#8211; Microadenomas<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/acromegaly-epidemiology-forecast\" target=\"_blank\"><strong>Acromegaly&nbsp;Epidemiology Segmentation in 7MM from 2017 to 2030<\/strong><\/a><\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalent Cases of Acromegaly<\/li>\n<li>Diagnosed Cases of Acromegaly<\/li>\n<li>Origin Specific Diagnosed Prevalent Cases of Acromegaly<\/li>\n<li>Diagnosed Cases of Acromegaly Based on Types of Adenomas\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acromegaly-epidemiology-forecast\" target=\"_blank\"><strong>Request for sample pages<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Acromegaly report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns<\/li>\n<li>The Acromegaly Epidemiology Report and Model provide an overview of the risk factors and global trends of Acromegaly in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)<\/li>\n<li>The report provides insight about the historical and forecasted patient pool of Acromegaly in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan<\/li>\n<li>The report helps to recognize the growth opportunities in the 7MM with respect to the patient population<\/li>\n<li>The report assesses the disease risk and burden and highlights the unmet needs of Acromegaly<\/li>\n<li>The report provides the segmentation of the Acromegaly epidemiology<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Table of contents<\/strong><\/p>\n<p style=\"text-align: justify;\"><span>1.&nbsp;Key Insights<\/span>&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span>2. Executive Summary of Acromegaly<\/span><\/p>\n<p style=\"text-align: justify;\"><span>3.&nbsp;Acromegaly: Disease Background and Overview<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>3.1.&nbsp;Introduction<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>3.2.&nbsp;Sign and Symptoms<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>3.3.&nbsp;Pathophysiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>3.4.&nbsp;Risk Factors<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>3.5.&nbsp;Diagnosis<\/span><\/p>\n<p style=\"text-align: justify;\"><span>4.&nbsp;Patient Journey<\/span><\/p>\n<p style=\"text-align: justify;\"><span>5.&nbsp;Epidemiology and Patient Population<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.1.&nbsp;Epidemiology Key Findings<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.2.&nbsp;Assumptions and Rationale: 7MM<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.3.&nbsp;Epidemiology Scenario: 7MM<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.3.1.&nbsp;Acromegaly Epidemiology Scenario in the 7MM (2017- 2030)<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.4.&nbsp;United States Epidemiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.4.1.&nbsp;Acromegaly Epidemiology Scenario in the United States (2017- 2030)<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.5.&nbsp;EU-5 Country-wise Epidemiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.5.1. Germany Epidemiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.5.1.1.&nbsp;Acromegaly Epidemiology Scenario in Germany (2017- 2030)<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.5.2. France Epidemiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.5.2.1.&nbsp;Acromegaly Epidemiology Scenario in France (2017- 2030)<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.5.3. Italy Epidemiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.5.3.1.&nbsp;Acromegaly Epidemiology Scenario in Italy (2017- 2030)<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.5.4. Spain Epidemiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.5.4.1.&nbsp;Acromegaly Epidemiology Scenario in Spain (2017- 2030)<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.5.5. United Kingdom Epidemiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.5.5.1.&nbsp;Acromegaly Epidemiology Scenario in the United Kingdom (2017-2030)<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.6. Japan Epidemiology<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>5.6.1.&nbsp;Acromegaly Epidemiology Scenario in Japan (2017- 2030)<\/span><\/p>\n<p style=\"text-align: justify;\"><span>6.&nbsp;Treatment Algorithm, Current Treatment, and Medical Practices<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>6.1.&nbsp;Acromegaly Treatment and Management<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>6.2.&nbsp;Acromegaly Treatment Algorithm<\/span><\/p>\n<p style=\"text-align: justify;\"><span>7.&nbsp;KOL Views<\/span><\/p>\n<p style=\"text-align: justify;\"><span>8.&nbsp;Unmet Needs<\/span><\/p>\n<p style=\"text-align: justify;\"><span>9.&nbsp;&nbsp;Appendix<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>9.1.&nbsp;Bibliography<\/span><\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>9.2.&nbsp;Report Methodology<\/span><\/p>\n<p style=\"text-align: justify;\"><span>10.&nbsp;DelveInsight Capabilities<\/span><\/p>\n<p style=\"text-align: justify;\"><span>11.&nbsp;Disclaimer<\/span><\/p>\n<p style=\"text-align: justify;\"><span>12.&nbsp;About DelveInsight<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=acromegaly-epidemiology-forecast-till-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=acromegaly-epidemiology-forecast-till-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8220;Acromegaly Epidemiology Forecast to 2030&#8242; report delivers an in-depth understanding of the disease, historical and forecasted Acromegaly epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/acromegaly-epidemiology-forecast-till-2030_501817.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-501817","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/501817","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=501817"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/501817\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=501817"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=501817"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=501817"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}